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BACKGROUND
The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop 
insulin-delivery system) in the home setting have not been established.
METHODS
In two multicenter, crossover, randomized, controlled studies conducted under free-living 
home conditions, we compared closed-loop insulin delivery with sensor-augmented pump 
therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night 
by 33 adults and overnight by 25 children and adolescents. Participants used the closed-
loop system for a 12-week period and sensor-augmented pump therapy (control) for a 
similar period. The primary end point was the proportion of time that the glucose level 
was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg 
per deciliter for children and adolescents.
RESULTS
Among adults, the proportion of time that the glucose level was in the target range was 
11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of 
the closed-loop system day and night than with control therapy (P<0.001). The mean glu-
cose level was lower during the closed-loop phase than during the control phase (differ-
ence, −11 mg per deciliter; 95% CI, −17 to −6; P<0.001), as were the area under the curve 
for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% 
CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, −0.3%; 95% CI, 
−0.5 to −0.1; P = 0.002). Among children and adolescents, the proportion of time with the 
nighttime glucose level in the target range was higher during the closed-loop phase than 
during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and 
the mean nighttime glucose level was lower (difference, −29 mg per deciliter; 95% CI, −39 
to −20; P<0.001). The area under the curve for the period in which the day-and-night glu-
cose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P = 0.03). 
Three severe hypoglycemic episodes occurred during the closed-loop phase when the 
closed-loop system was not in use.
CONCLUSIONS
Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared 
with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, 
and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and 
others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and 
NCT01778348.)
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Intensive insulin therapy is the stan-dard of care for type 1 diabetes but is limited by the risk of hypoglycemia,1 which leads to 
failure in achieving treatment goals for most 
patients in all age groups.2,3 Among patients with 
type 1 diabetes, hypoglycemia is common, has a 
major effect on patients’ quality of life and psy-
chological well-being,4 and may cause seizures, 
which is of particular concern during the over-
night hours in children and adolescents.5 New 
approaches (e.g., continuous glucose monitoring) 
can improve glycemic control when the patient 
wears the sensors on a regular basis.6,7 If insulin 
delivery is linked to sensor glucose levels during 
the use of an insulin pump that has a threshold-
suspend feature,8 which temporarily interrupts 
insulin delivery at preset glucose levels, the risk 
of hypoglycemia may be reduced.
The artificial beta cell, or closed-loop insulin-
delivery system, expands on the concept of sensor-
responsive insulin delivery. The closed-loop sys-
tem differs from conventional pump therapy and 
threshold-suspend approaches in that it uses a 
control algorithm that autonomously and con-
tinually increases and decreases the subcutane-
ous delivery of insulin on the basis of real-time 
sensor glucose levels.9
After extensive studies under controlled labo-
ratory settings,10-14 investigations of closed-loop 
systems in transitional outpatient settings that 
incorporated remote monitoring and supervision 
by research staff members in hotels15 or at dia-
betes camps16,17 have shown improved glucose 
control and a reduced risk of hypoglycemia.16-19 
However, studies involving patients under at-
home, free-living conditions have been limited 
to 1-week, day-and-night use of the closed-loop 
system in adults20 and to overnight use of a 
closed-loop system for 3 to 6 weeks in adolescents 
and adults.21-23 The evaluation of the closed-loop 
system in children 12 years of age or younger in 
free-living settings is also desirable.
Here we present the results of two multi-
center, 12-week, free-living home trials — one 
involving the day-and-night use of a closed-loop 
system in adults and the other the overnight use 
of a closed-loop system in children and adoles-
cents. We hypothesized that the extended use of 
closed-loop insulin delivery without remote mon-
itoring or close supervision would be feasible, 




All the participants had type 1 diabetes, as de-
fined by the World Health Organization, and had 
received insulin-pump therapy for at least 6 months. 
We recruited adults who were at least 18 years 
of age and had a glycated hemoglobin level of 
7.5 to 10% (58 to 86 mmol per mole of nongly-
cated hemoglobin) and children and adolescents 
who were 6 to 18 years of age and had a gly-
cated hemoglobin level of less than 10%. Details 
regarding the inclusion and exclusion criteria are 
provided in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.
Study Oversight
The two study protocols were approved by inde-
pendent research ethics committees (one central 
ethics committee for the study involving chil-
dren and one ethics committee in each country 
for the study involving adults) and by the regula-
tory authority in the United Kingdom (Medicines 
and Healthcare Products Regulatory Agency). The 
study involving adults also received approval from 
regulatory authorities in Germany (Federal Insti-
tute for Drugs and Medical Devices) and Austria 
(Austrian Agency for Health and Food Safety).
All the adult participants provided written in-
formed consent. In the study involving children 
and adolescents, participants who were 16 years 
of age or older and the parents or guardians of 
participants who were younger than 16 years of 
age provided written informed consent; written 
assent was obtained from participants younger 
than 16 years of age. The safety aspects of the 
two studies were overseen by an independent 
data and safety monitoring board.
Abbott Diabetes Care supplied discounted con-
tinuous glucose-monitoring devices, sensors, and 
details of the communication protocol to facili-
tate real-time connectivity. Diasend provided dis-
counted hardware and software platforms for 
data upload. Abbott Diabetes Care read the 
manuscript before it was submitted for publica-
tion but had no role in its revision. No sponsor 
had any other role in the design of the study, the 
collection, analysis, or interpretation of the data, 
or the writing of the report. The authors vouch 
for the accuracy and completeness of the data 
and for the fidelity of the study to the protocols. 
Two of the authors hold patents related to closed-
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loop insulin-delivery systems and systems for 
insulin delivery that use various measurement-
error models.
Study Design
Characteristics of the Two Studies
The two studies were open-label, multicenter, 
crossover, randomized, controlled trials (Fig. S1 
in the Supplementary Appendix). The study in-
volving adults was conducted in the United 
Kingdom, Germany, and Austria,24 and the study 
involving children and adolescents was conducted 
at three sites in the United Kingdom. All the 
participants were randomly assigned to receive 
either 12 weeks of automated closed-loop insulin 
delivery (intervention period) first and sensor-
augmented pump therapy (control period) second, 
or vice versa. The analysis of the closed-loop 
phase included data from the combined closed-
loop phases of the two randomization sequences; 
the analysis of the control phase also included 
combined data. The study protocols are available 
at NEJM.org.
Identical insulin pumps and continuous glu-
cose-monitoring devices were used during the 
two treatment periods in the two trials; continu-
ous glucose-monitoring devices were worn dur-
ing the two study periods. Participants were not 
remotely monitored or supervised, and they per-
formed their usual free-living daily activities. Par-
ticipants were free to consume any meals of their 
choice. As a precaution, during the first 2 weeks 
of the study periods, participants were advised 
against international travel and the use of the 
closed-loop system during exercise. All the par-
ticipants were provided with a telephone number 
for a 24-hour helpline to contact the study team 
in the event of study-related issues.
Each participant had an identical number of 
planned contacts with the study team during the 
two treatment periods. Blood samples were ob-
tained for the measurement of glycated hemo-
globin levels at enrollment and before and after 
each treatment period. C-peptide levels were 
measured at enrollment during a period when 
participants did not have hypoglycemia (i.e., had a 
blood glucose level ≥72 mg per deciliter [4.0 mmol 
per liter]).
The two treatment interventions were sepa-
rated by a washout period (lasting 4 to 6 weeks 
in adults and 3 to 4 weeks in children and ado-
lescents). During the washout period, the partici-
pants could continue using the study insulin 
pump with their standard pump settings.
Study Involving Adults
After receiving training regarding the use of the 
insulin pump and the continuous glucose-moni-
toring device, participants underwent a run-in 
period lasting 4 to 6 weeks. During this period, 
participants came to the research center at weekly 
intervals for adjustment of pump therapy by the 
study team according to a prespecified sequence 
of written instructions for basal and meal-related 
insulin-dose adjustments. Participants were re-
quired to use the study devices for at least 10 days 
during the last 2 weeks of the run-in period be-
fore randomization.
During the intervention period, participants 
used the closed-loop system during the day and 
night while they were at home, at work, and dur-
ing holidays. Participants performed insulin meal-
priming bolus calculations by entering carbohy-
drate amount and fingerstick capillary glucose 
measurements into the standard bolus calculator.
Study Involving Children and Adolescents
After receiving training regarding the use of the 
insulin pump and the continuous glucose-mon-
itoring device, participants underwent a run-in 
period lasting 2 to 8 weeks. Data obtained dur-
ing this period were used for adjustment of the 
therapy. Participants were required to use the 
study devices for at least 12 days during the run-
in period before randomization.
During the intervention period, participants 
used the closed-loop system overnight while at 
home during school terms and holidays. Partici-
pants were instructed to initiate the system at 
home after their evening meal or at bedtime at 
the latest and to discontinue it before breakfast 
the next morning.
Closed-Loop System
An identical, individually adapting, model-predic-
tive-control treat-to-target algorithm (a control 
approach relying on a dynamic model of glucose 
regulation to calculate the insulin delivery that 
is predicted to achieve desirable glucose levels) 
was used in the two studies. Every 12 minutes, 
the control algorithm calculated an insulin infu-
sion rate that was automatically sent wirelessly 
to the study insulin pump (Figs. S2 and S3 in the 
Supplementary Appendix). A hybrid closed-loop 
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approach was applied in the day-and-night study 
involving adults, in which participants addition-
ally administered prandial insulin using the 
standard bolus calculator. The control algorithm 
was initialized with the use of a preprogrammed 
basal insulin delivery downloaded from the study 
pump, and the participant’s weight and total 
daily insulin dose were entered at setup. Further 
details are provided in the Supplementary Ap-
pendix.
Study End Points
The primary end point in the study involving 
adults was the proportion of time that the glu-
cose level, as measured by the continuous glu-
cose-monitoring device, was in the target range 
of 70 to 180 mg per deciliter (3.9 to 10.0 mmol 
per liter) during the 12-week study periods. The 
primary end point in the study involving chil-
dren and adolescents was the proportion of time 
that the nocturnal glucose level, as detected by 
the sensor, was in the target glucose range of 70 
to 145 mg per deciliter (3.9 to 8.0 mmol per liter) 
during the 12-week study periods. Secondary end 
points were insulin delivery, the glycated hemo-
globin level, mean sensor glucose levels, the vari-
ability of the glucose level, and the time spent 
below and above the relevant glucose ranges 
during day-and-night, daytime, and overnight 
periods (see the Supplementary Appendix).
Statistical Analysis
Statistical analyses were performed on an inten-
tion-to-treat basis. We compared the respective 
values obtained during the 12-week intervention 
and control periods using a least-squares repeated-
measures regression model, adjusting for the 
period effect as a covariate and accounting for 
the correlated data from the same participant 
with the use of an unstructured covariance ma-
trix. The hypothesis testing was ordered first to 
consider the primary end points at the 0.05 level 
and then to move to testing the secondary end 
points individually at the 0.05 level without any 
control for multiplicity. A sensitivity analysis was 
used to assess the effect of withdrawal of par-
ticipants from the study. All P values are two-
sided (see the Supplementary Appendix).
R esult s
Participants
We screened 75 patients, of whom 58 were eli-
gible and underwent randomization (Table 1). 
All the participants had a C-peptide level of less 
than 33 pmol per liter during the initial assess-
ment, measured at a time when they did not 
have hypoglycemia (i.e., had a blood glucose 
level ≥72 mg per deciliter), except for four par-
ticipants in the study involving children and 
adolescents who had levels of 40, 40, 170, and 
530 pmol per liter. Four adults had stable micro-
vascular complications, and no adult had any 
macrovascular complications; none of the chil-
dren and adolescents had either microvascular 
or macrovascular complications. One adult par-
ticipant and one adolescent participant voluntarily 
withdrew during the washout phase because of 
issues unrelated to the closed-loop study (Fig. S4 
in the Supplementary Appendix).
End Points in the Study Involving Adults
Table 2 details the primary and secondary end 
points in the study involving adults. The sensor 
glucose levels and insulin-delivery profiles are 
shown in Figure 1A. The proportion of time that 
the glycated hemoglobin level was in the target 







Sex — no. (%)
Female 15 (45) 11 (44)
Male 18 (55) 14 (56)
Age — yr 40.0±9.4 12.0±3.4
Weight — kg 77.5±15.0 43.9±16.6
BMI† 25.5±4.4 18.9±3.5
BMI z score — 0.3±1.0
Duration of diabetes — yr 20.9±9.3 4.7±2.6
Duration of pump use — yr 7.8±5.9 3.3±1.8
Total daily insulin dose — U/kg/day 0.62±0.15 0.89±0.24
Glycated hemoglobin at screening
Percent 8.5±0.7 8.1±0.9
Millimoles per mole of non- 
glycated hemoglobin
69±7 65±10
*  Plus–minus values are means ±SD.
†  The body-mass index (BMI) is the weight in kilograms divided by the square 
of the height in meters.
Table 1. Characteristics of the Study Participants at Baseline.*
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greater during the intervention period than dur-
ing the control period — by a mean of 11.0 
percentage points (95% confidence interval [CI], 
8.1 to 13.8; P<0.001). The mean glucose level 
was significantly lower with day-and-night use 
of the closed-loop system than with the control 
system (P<0.001), as was the time spent above 
the target range (P<0.001). The time that the 
glucose level was less than 70 mg per deciliter 
and less than 50 mg per deciliter (2.8 mmol per 
liter) was significantly less with the closed-loop 
system than with the control system (P = 0.02 
and P<0.001, respectively). The relative burden of 
hypoglycemia, as measured by the area under 
the curve when the sensor glucose level was less 
than 63 mg per deciliter (3.5 mmol per liter), 
was significantly lower by 39% (95% CI, 24 to 
51) during the intervention period than during 
the control period (P<0.001). After adjustment of 
the sensor-augmented pump therapy during the 
run-in phase, the glycated hemoglobin level was 
lower during the day-and-night closed-loop insu-
lin-delivery period than during the control period 
(P = 0.002).
Glucose variability, measured both as the 
standard deviation of the sensor glucose level 
and as the coefficient of variation of the sensor 
glucose level between days, was significantly 
lower with day-and-night use of the closed-loop 
system than with the control system. During the 
intervention period, the time during which the 
glucose level was in target range was greater and 
the mean overnight glucose level and the glycated 
hemoglobin level were lower with the closed-
loop system than with the control system, with-
out an increase in the total daily insulin use 
(P = 0.57) (Table S1 in the Supplementary Ap-
pendix). Higher basal insulin delivery during 
the intervention period than during the control 
period (P<0.001) was offset by lower bolus deliv-
ery during the intervention period (P = 0.002), 
presumably owing to lower glucose levels that 
resulted in reduced correction boluses.
Insulin delivery during the daytime (8:01 a.m. to 
11:59 p.m.) and overnight (midnight to 8:00 a.m.) 
were similar during the two study periods. The 
day-and-night closed-loop system was used for a 
median of 20.2 hours per day, and participants 
wore the continuous glucose monitor for a me-
dian of 22.7 hours per day. During the control 
period, participants wore the continuous glucose 
monitor for a median of 22.9 hours per day.
Overnight end points were similar to those 
during the 24-hour period. The overnight mean 
glucose level was significantly lower with the 
closed-loop system than with the control system 
(P<0.001), and the proportion of time that the 
glucose level was within the overnight target 
range was greater with the closed-loop system 
(P<0.001) (Fig. 2). The proportion of time that 
patients had hypoglycemia, the number of nights 
that the sensor glucose level was less than 63 mg 
per deciliter for at least 20 minutes, and the area 
under the curve when the sensor glucose level 
was less than 63 mg per deciliter were all sig-
nificantly lower with the closed-loop system than 
with the control system.
The daytime end points are shown in Table S2 
in the Supplementary Appendix. We observed in 
a lower mean glucose level, an increased propor-
tion of time spent within the target range, and a 
reduced proportion of time spent above the tar-
get range. The time that the glucose level was 
less than 50 mg per deciliter was significantly 
lower with the closed-loop system than with the 
control therapy (P = 0.02).
End Points in the Study Involving Children 
and Adolescents
The primary and secondary end points in the 
study involving children and adolescents are 
shown in Table 2. The sensor glucose levels and 
insulin-delivery profiles are shown in Figure 1B. 
The proportion of nocturnal time that the glu-
cose level was in the target range (primary end 
point) was significantly greater during the inter-
vention period than during the control period by 
a mean of 24.7 percentage points (95% CI, 20.6 to 
28.7; P<0.001). The mean overnight glucose level 
was significantly lower with the closed-loop 
system than with the control system (P<0.001) 
(Fig. 2), as was the time spent above the target 
range (P<0.001). The proportion of time that the 
sensor glucose level indicated a blood glucose 
level below 70 mg per deciliter was less than 4%, 
and the proportion of the time that the sensor 
glucose level indicated a blood glucose level below 
50 mg per deciliter was less than 1%; these val-
ues were similar during the two study periods.
Glucose variability, as measured by the stan-
dard deviation of the overnight sensor glucose 
level and the coefficient of variation between 
nights, was significantly less with the closed-
loop system than with the control system. 
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Nocturnal glucose levels were lower during the 
intervention period than during the control pe-
riod without an increase in the total overnight 
insulin dose (P = 0.11) (Table S1 in the Supple-
mentary Appendix). Daytime insulin delivery 
and the total daily insulin dose were similar 
during the two study periods. The overnight 
closed-loop system was operating for a median 
of 9.3 hours per day. Participants wore the 
 continuous glucose monitor for a median of 
22.1 hours per day during the intervention peri-
od and for a median of 20.3 hours per day dur-
ing the control period (Table S3 in the Supple-
mentary Appendix).
End points calculated over the 24-hour period 
are shown in Table 2. The 24-hour mean glucose 
level was significantly lower with overnight use 
of the closed-loop system than with the sensor-
augmented pump therapy (P = 0.01), and the 
proportion of time spent within the wider (70 to 
180 mg per deciliter) target range was signif-
icantly greater with the closed-loop system 
(P<0.001). The time that the glucose level was 
below 50 mg per deciliter over the 24-hour pe-
riod tended to be lower with the closed-loop 
system than with the control system (P = 0.05). 
The burden of hypoglycemia during the 24-hour 
period, as measured by the area under the curve 
when the sensor glucose level was less than 
63 mg per deciliter, was significantly lower 
by 42% (95% CI, 4 to 65) during the interven-
tion period than during the control period 
(P = 0.03).
The comparison of end points during daytime 
is shown in Table S2 in the Supplementary Ap-
pendix. The mean glucose level and the propor-
tions of time spent within, above, and below the 
wider target range were similar during the two 
study periods. The area under the curve when 
the sensor glucose level was less than 63 mg per 
deciliter was significantly lower during the inter-
vention period than during the control period 
(P = 0.04). The time that the glucose level was 
below 50 mg per deciliter tended to be lower 
during the intervention period than during the 
control period (P = 0.07), a finding that was at-
tributed to the fact that the amount of time that 
the level was below 50 mg per deciliter was 79% 
(95% CI, 34 to 93) lower in the intervention pe-
riod than in the control period during the post-
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Adverse Events
Details of all the adverse events are provided in 
Table 3. One episode of severe hypoglycemia oc-
curred in an adult participant during the inter-
vention period when the closed-loop system was 
not in use because of loss of connectivity (low 
battery) and the participant was receiving insu-
lin at the rate supplied by the study insulin pump 
(Fig. S5 in the Supplementary Appendix). In the 
study involving children and adolescents, one 
adolescent participant had two severe hypoglyce-
mic episodes (seizures) during the intervention 
period; these episodes required third-party as-
sistance but did not result in hospital admission 
(Fig. S6 and S7 in the Supplementary Appendix). 
During the two episodes, the closed-loop system 
was not in use (closed-loop system not turned on 
and lack of pump connectivity) and the partici-
pant was using sensor-augmented pump therapy. 
The adult and adolescent participants both re-
covered fully, without clinical sequelae.
Discussion
Our findings show the feasibility, safety, and 
efficacy of 12-week day-and-night application of 
closed-loop insulin delivery in adults and over-
night application in children and adolescents 
under free-living conditions. Among adults, glu-
cose control was better with day-and-night use 
of a hybrid closed-loop system than with a con-
trol system consisting of a sensor-augmented 
pump: the proportion of time that the glucose 
level was in the target range was greater with 
Figure 1. Sensor Glucose Levels and Insulin Delivery.
Shown are the median sensor glucose levels and the median values for insulin delivery during the day-and-night closed-loop study involv-
ing adults (Panel A) and the overnight closed-loop study involving children and adolescents (Panel B). The bands indicate interquartile 
ranges. To convert the values for glucose to millimoles per liter, multiply by 0.05551.
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the closed-loop system, and the mean glucose 
level and the risk of hypoglycemia were lower; 
the glycated hemoglobin level was also lower. 
Among children and adolescents, the amount of 
time that the nocturnal sensor glucose level was 
within the target range was greater with over-
night use of the closed-loop system than with 
the control system and the mean glucose level 
was lower. Extended benefits from overnight use 
of the closed-loop system in children and adoles-
cents were seen over the full 24-hour period, and 
the reduced burden of hypoglycemia was attrib-
uted mainly to the post-breakfast period.
Hypoglycemia is a key factor that limits the 
use of intensive insulin therapy in patients with 
type 1 diabetes.1 Systems with threshold-suspend 
control25 and predictive low-glucose suspend 
control26 may reduce the risk of hypoglycemia, 
but the systems are not designed to step up in-
sulin delivery and do not address the issue of 
hyperglycemia. The advantage of a closed-loop 
system is the responsive, graduated modulation 
of insulin delivery, both below and above the 
preset pump regimen, which allows for improve-
ments in the proportion of time spent in target 
glucose range and the lowering of the mean 
glucose level without increasing the risk of hy-
poglycemia. Even though the pump therapy was 
appropriately adjusted in adults during the run-
in period, the glycated hemoglobin level was fur-
ther reduced from the end of the run-in period 
with the closed-loop system. More consistent 
glucose values were observed with the closed-
loop system than with the control therapy, de-
spite high day-to-day variability in insulin re-
quirements. No apparent trend was seen in the 
proportion of time during which the glucose 
level was in the target range over the 12-week 
intervention period, which implies rapid day-to-
day adaptation by the control algorithm (Fig. S8 
in the Supplementary Appendix).
The current study extends and confirms find-
ings from our previous, shorter trials during free 
daily living in adults and adolescents.20,22,23 Other 
studies of closed-loop systems in the outpatient 
or home setting have been performed over a 
shorter duration and under conditions of remote 
monitoring or close supervision.21,27,28 Adults and 
adolescents in an outpatient setting had a lower 
mean glucose level with the use of a dual-hor-
mone (insulin and glucagon) closed-loop system 
for 5 days than with conventional therapy, with 
a lower risk of hypoglycemia in adults but not in 
adolescents.18 Among children and adolescents 
at a diabetes camp, the risk of hypoglycemia 
was lower with a dual-hormone system used for 
3 nights than with an insulin-alone closed-loop 
system, with a similar sensor glucose level.19 
Dual-hormone systems may provide additional 
protection against hypoglycemia29 but are cur-
rently limited by the need to reconstitute gluca-
gon daily and by the use of a second pump to 
Figure 2. Overnight Glucose Levels.
Shown are the individual overnight mean sensor glucose levels in adults (Panel A) and in children and adolescents 
(Panel B). Adults used the closed-loop systems day and night and children and adolescents used the closed-loop 
systems overnight. The size of the bubble indicates the proportion of time overnight during which the glucose level 
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deliver glucagon through a separate infusion set, 
which increases the burden and complexity.
The strengths of our studies are the multi-
center design and, in the study involving adults, 
the multinational design, which support gener-
alizability. In an effort to assess the real-world 
use and applicability of a new technology, we did 
not apply remote monitoring or close supervi-
sion. We did not restrict participants’ dietary 
intake or, after the initial 2 weeks, physical ac-
tivity or geographical movements. Participants 
were allowed to travel and to use the system 
when driving. The comparator was sensor-aug-
mented insulin-pump therapy. An efficient cross-
over design was adopted; confounding study-
period or carryover effects were not detected for 
the primary end points (Tables S4 and S5 in the 
Supplementary Appendix). We applied clinically 
relevant and commonly adopted target glucose 
ranges to differentiate between fasting or over-
night conditions and nonfasting conditions. 
Adherence to wearing the glucose sensor in the 
two participant groups was high and similar 
(>20 hours per day) in the two study periods. 
The study was limited by the number of devices 
each participant had to use. A more adaptive 
control algorithm might further enhance day-
time benefits.
In conclusion, we found that extended use of 
a closed-loop system at home over a period of 
12 weeks during free daily living without close 
supervision is feasible in adults, children, and 
adolescents with type 1 diabetes. Improvements 
in glucose control and reductions in the burden 
of hypoglycemia were observed. Among adults, 
the glycated hemoglobin level was lower with 
the use of a closed-loop system day and night 
than with a sensor-augmented insulin pump, 
even when the insulin pump was adjusted ap-
propriately.


















Respiratory tract infection 0 6 (18) 6 (18) 0 0 0 0 1 (4)
Gastroenteritis 0 2 (6) 3 (9) 0 0 0 0 0
Shingles 0 0 1 (3) 0 0 0 0 0
Knee-joint arthralgia 0 1 (3) 0 0 0 0 0 0
Fractured finger 0 0 0 0 0 1 (4) 0 0
Inflammation at site of sensor 
insertion
0 2 (6) 4 (12) 0 0 1 (4) 0 0
Ketonemia related to inter- 
current illness
0 1 (3) 1 (3) 0 0 2 (8) 0 0
Hyperglycemia related to 
infusion-set occlusion
0 6 (18) 4 (12) 0 0 2 (8) 0 0
Severe hypoglycemia 0 1 (3) 0 0 0 2 (8) 0 0
Hospitalization
Due to inguinal hernia 0 1 (3) 0 0 0 0 0 0
Due to renal calculi 0 0 1 (3) 0 0 0 0 0
Due to peritonsillar abscess 0 0 1 (3) 0 0 0 0 0
Due to gastroenteritis 0 0 0 0 1 (4) 0 0 0
*  Adults used the closed-loop system day and night, and children and adolescents used the closed-loop system overnight only. In the two 
studies, the closed-loop (intervention) and the control periods each lasted 12 weeks. In the study involving adults, the run-in period lasted 4 to 
6 weeks and the washout period lasted 4 to 6 weeks. In the study involving children and adolescents, the run-in period lasted 2 to 8 weeks and 
the washout period lasted 3 to 4 weeks.
Table 3. Adverse Events.*
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